Biostatistician: Michael A. Newton, PhD – Cancer Genetics Program
Collaborators: Paul Ahlquist, PhD and Paul F. Lambert, PhD – Human Cancer Virology Program
I/IIa clinical trial in 22 stage D0 prostate cancer patients was conducted to evaluate the safety of a DNA-based vaccine encoding Prostatic Acid Phosphatase (PAP).
Working with Drs. Lambert and Ahlquist, Dr. Newton analyzed whole-genome profiles from human tissue samples. Findings provided novel biomarkers for early detection and emphasized the potential value of targeting E6 and E7 function in the treatment of HPV+ cancers.
Biostatisticians: Jens C. Eickhoff, PhD – Experimental Therapeutics Program; KyungMann Kim, PhD – Chemoprevention Program
Collaborators: Jill M. Kolesar, PharmD – Experimental Therapeutics Program; Howard H. Bailey, MD – Chemoprevention Program
Motivated by their collaboration with Drs. Kolesar and Bailey, Drs. Kim and Eickhoff developed optimal clinical trial designs for pharmacogenomics-driven targeted therapies that directly integrated information about biomarkers and clinical outcomes as they become available. The design efficiently identified patients who benefit most from a targeted therapy. There were substantial savings in the sample size requirements when compared to alternative designs.
Biostatistician: Ronald E. Gangnon, PhD – Cancer Control Program
Collaborators: Amy Trentham-Dietz, PhD, Jane McElroy, PhD, Patrick Remington, PhD, and Polly A. Newcomb, PhD – Cancer Control Program
Using geocoded residential locations for case-control study participants, Dr. Gangnon utilized a generalized additive logistic regression model to estimate geographic risk as a local odds ratio using a two-dimensional thin plate spline while adjusting for established risk factors. Results suggest that established breast cancer risk factors do not explain long-standing observations of higher breast cancer mortality in eastern WI counties.